An analysis finds that CVS Health's planned corporate breakup largely preserves the vertical integration model that has drawn political and regulatory criticism, raising questions about whether the restructuring will meaningfully change market dynamics.
GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, according to a Wall Street Journal interview with a company scientist. The expansion follows a dealmaking spree as the British drugmaker accelerates its return to oncology.
Genmab's experimental antibody-drug conjugate Rina-S reduced the risk of death by 57% compared to chemotherapy in patients with advanced ovarian cancer, according to phase 3 trial results presented at ESMO. The Danish drugmaker's shares surged over 12% on the news.
Abbott announced plans to separate its nutrition business, which includes Similac infant formula, into a publicly traded company. The unit has been at the center of years of litigation over management of a baby formula facility where deadly bacteria was found.
Novo Nordisk announced it cut 13,000 jobs in the past year and outlined plans to diversify beyond obesity drugs with new pipeline assets and bolt-on acquisitions. CEO Mike Doustdar faced investor skepticism about pricing power and strategy ahead of patent expiries.
Biohaven Pharmaceuticals has entered into a licensing agreement with South Korean drugmaker SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, in a deal worth up to $795 million.
Global investment firm KKR has signed a definitive agreement to acquire Medicover India, the Indian hospital business of Stockholm-based Medicover, in a deal valued at approximately $1.3 billion (₹10,000-14,250 crore). The acquisition marks KKR's largest healthcare deal in India and includes a 24-hospital network, with plans for additional investment of ₹3,000-4,000 crore for expansion.
Supernus Pharmaceuticals and Indivior Pharmaceuticals announced an all-stock merger to create a combined company with approximately $2.2 billion in annual revenue and a portfolio of 11 commercialized medicines focused on neurological, psychiatric, and addiction-related conditions. The deal, described as a merger of equals, is expected to generate $125 million in cost savings.
Snap released its first consumer augmented-reality glasses priced at $2,195, positioning them as the future of AI-age interaction. CEO Evan Spiegel defended the product against activist investor pressure to shut down or spin off the hardware division.